Company profile

Evommune, Inc.

Pipeline2 assets

EVO756EVO756 / MRGPRX2 / Oral small-molecule antagonist / Chronic inflammatory diseases
Chronic Spontaneous UrticariaPhase 2Atopic DermatitisPhase 2MigrainePhase 1
EVO301EVO301 / IL-18 / Long-acting injectable SAFA-IL-18BP fusion protein / Chronic inflammatory diseases
Atopic DermatitisPhase 2Ulcerative ColitisPhase 1

Oct 1, 2026

Trial Results • Phase 2EADV late-breaking oral presentation Thu, Oct 1, 2026, 8:00 AM EDT

Sep 23, 2026

Presentation / Abstract • Phase 2Late-breaking oral presentation Thu, Oct 1, 2026, 4:30 PM CEST

Sep 8, 2026

Trial Results • Phase 2Top-line results Tue, Sep 8, 2026

Aug 6, 2026

Jul 30, 2026

Trial Start • Phase 2Trial initiation Thu, Jul 30, 2026, 8:00 AM EDT

Jun 29, 2026

Trial Results • Phase 2Top-line results Mon, Jun 29, 2026, 8:30 AM EDT

May 7, 2026